You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Genetron will provide clinical trial genomic testing and companion diagnostic development services for InnoCare's biomarker-driven oncology drug development.
The firm will apply the funds to development of a next generation of its digital PCR system as well as expansion in Asia.
On Monday Qiagen reiterated its preliminary 2019 earnings figures and addressed an investor's wrath, while Guardant Health highlighted its cancer testing plans.
The startup is exploring options with potential partners and plans to bring a urinary tract infection test through regulatory channels in the next two years.
Biocartis' Idylla called some colorectal cancer samples negative that Sysmex Inostics's OncoBEAM called positive, but the clinical implications may be complex.
The life science segment saw strong sales in Droplet Digital PCR offset by sales the firm's process media product line.
The firm said it can detect circulating tumor DNA with a mutational allele frequency of 0.001 percent, enabled by digital PCR and the firm's proprietary chemistry.
The company's full-year revenues rose 6 percent and were slightly higher than the consensus Wall Street estimate.
The firm plans to add more oncology tests, NIPTs and newborn screening assays through in-house development and partnerships with third-party assay makers.
The new chip enables the firm's digital PCR system to test up to 240 samples per day, and also uses lower volumes of sample input.
New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.
According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.
The US National Institutes of Health has a new initiative to address structural racism in biomedical research.
In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.